Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Biotech funding challenges and government funding pressure have negatively impacted companies supporting biopharmaceutical development like contract research organization (CRO) ICON. This has pushed...
— Dmitry Khaykin, Deepon Nag
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on ICON Public Limited Company
ICON Plc fell sharply after announcing an internal investigation into revenue recognition, which the manager views as a temporary overreaction since the restatement impact is expected to be under 2%. The manager added...
LVS Advisory divested from Icon Plc after deeper research revealed that its aggressive M&A strategy created project disruptions, high employee turnover, and substantial debt. Concluding that Medpace's...
LVS purchased Icon Plc expecting strong CRO sector tailwinds and an attractive valuation, but deeper fundamental research revealed critical flaws. The firm's heavy...
More institutional theses from ClearBridge Investments Large Cap Value
CVS Health Corporation operates an integrated healthcare enterprise spanning retail pharmacies, pharmacy benefit management via Caremark, and healthcare benefits through Aetna. ClearBridge maintains an...
Nvidia Corporation is the premier global designer of advanced graphics processing units (GPUs) and integrated compute platforms powering generative artificial intelligence, high-performance computing, and enterprise automation. ClearBridge initiated a...